Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders

被引：40

作者：

Banati, Richard ^{[1
]}

Hickie, Ian B. ^{[1
]}

机构：

[1] Univ Sydney, Brain & Mind Res Inst, Ramaciotti Ctr Mol Imaging, Sydney, NSW 2006, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2009年 / 190卷 / 04期

关键词：

IN-VIVO DETECTION; BIPOLAR DISORDER; MICROGLIAL ACTIVATION; HIPPOCAMPAL VOLUMES; GLIAL ACTIVATION; VITAMIN-D; BRAIN; EXPRESSION; IDENTIFICATION; CYTOTOXICITY;

D O I：

10.5694/j.1326-5377.2009.tb02371.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We propose that various measures of brain structure or function, gene expression and proteomic technologies can be used to guide better treatment of schizophrenia and other psychotic disorders. These measures are not used to establish a specific diagnosis. Their purpose is to predict variations in underlying illness activity that predict severity, course of clinical illness, or other morbidity. We propose a new instrument that uses a composite scoring system of systemic biomarkers of illness-related changes in health status: the Brain and Mind Research Institute Biomarker Index. This may permit comparison of biological dysfunction among patients who are at similar points in their illness or have similar clinical features. A specific example of the use of a novel positron emission tomography marker of progressive brain disease in patients with schizophrenia is described.

引用

页码：S26 / S32

页数：7

共 52 条

[31] Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys [J].

Kanaan, Nicholas M. ;

Kordower, Jeffrey H. ;

Collier, Timothy J. .

GLIA, 2008, 56 (11) :1199-1214

[32] Schizophrenia proteomics: biomarkers on the path to laboratory medicine? [J].

Lakhan, Shaheen Emmanuel .

DIAGNOSTIC PATHOLOGY, 2006, 1 (1)

[33] Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes [J].

McDonald, C ;

Bullmore, ET ;

Sham, PC ;

Chitnis, X ;

Wickham, H ;

Bramon, E ;

Murray, RM .

ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (10) :974-984

[34] Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions [J].

McGorry, Patrick D. ;

Hickie, Ian B. ;

Yung, Alison R. ;

Pantelis, Christos ;

Jackson, Henry J. .

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2006, 40 (08) :616-622

[35] Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera [J].

McGrath, J ;

Eyles, D ;

Mowry, B ;

Yolken, R ;

Buka, S .

SCHIZOPHRENIA RESEARCH, 2003, 63 (1-2) :73-78

[36] Hypothesis: Is low prenatal vitamin D a risk-modifying factor for schizophrenia? [J].

McGrath, J .

SCHIZOPHRENIA RESEARCH, 1999, 40 (03) :173-177

[37] A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology [J].

McGrath, John ;

Saha, Sukanta ;

Welham, Joy ;

El Saadi, Ossama ;

MacCauley, Clare ;

Chant, David .

BMC MEDICINE, 2004, 2 (1)

[38]

Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249

[39]

Müller N, 1999, EUR ARCH PSY CLIN N, V249, P62

[40] A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder [J].

Murray, RM ;

Sham, P ;

Van Os, J ;

Zanelli, J ;

Cannon, M ;

McDonald, C .

SCHIZOPHRENIA RESEARCH, 2004, 71 (2-3) :405-416

← 1 2 3 4 5 6 →